A sophisticated research tool that allows to see the fundus picture of the area which is being stimulated. Besides it also includes the refractive pupil camera enabling the examiner to switch between
The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma.
Kelly Punches
... instrument provides standardized glare testing. I...ces for the evaluation of glare disability. For ca...ecisely calibrated to simulate two on-coming halog...The glare level can be adjusted to simulate other ...
Medicine Products:(Date:9/7/2008)...s also been linked recently to patient deaths , ...w once-a-week formulation of the injectable diabet...an the older twice-a-day formulation, researchers ..., [the new formulation] provided the remarkable ad...ol and good gastrointestinal tolerability," said D...
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Lieuten...proclamation acknowledging Sept. 11 as,American Re...nsylvania and The American Red Cross ask donors,of... those who lost their,lives on 9/11 and to help st...ion can save up to three lives., "We all remember...
(Date:9/5/2008)...xplain how theoretical ,anti-cloak, could bring ob...(HealthDay News) -- Just in case someone develops ...sts say they know how to uncloak the objects it hi...s Express , certain materials underneath an invisi...een again. , Researchers at Shanghai Jiao Tong ...
(Date:9/5/2008)... Mass., Sept. 5 /PRNewswire/ -- Arthrosurface, Inc...of less-invasive joint,resurfacing systems, announ...A to begin its pivotal investigation for its line ... that "there are no outstanding safety,concerns" w... Arthrosurface has been evaluating the safety and ...
Breaking Medicine News(10 mins):Health News:Once-Weekly Diabetes Drug Boosts Blood Sugar Control 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2(Date:9/8/2008)...t. 8 /- Medarex, Inc.,(Nasd...estone payment for an,undisclosed amount from its ... payment is a result of the submission of an Inves...r the clinical development of an antibody,generate...receive future,milestone payments and royalties sh...
(Date:9/6/2008)...ety and Efficacy of First-in-Class Neurally Acting...of Acute Migraine, LONDON, Sept. 6 /...technology company focusing on therapies for centr...sults of its lead compound COL-144,in the treatmen...-144 was,safe and effective in relieving migraine ...
(Date:9/5/2008)... Calif., Sept. 5 /- SARcode...olecule LFA-1 inhibitors,to treat inflammatory dis...SNSS) today announced SARcode,s initiation of a Ph...duct candidate for T-cell mediated ophthalmic,dise...greement providing,SARcode with an exclusive licen...
(Date:9/4/2008)...ept. 4 /- BioForm Medical,...otal clinical study of,Polidocanol, conducted in G...rik KREUSSLER & Co. GmbH (Kreussler), successfully...tted to FDA as part of a New Drug Application,(NDA...the EASI (Efficacy and safety of,Aethoxysklerol co...
Breaking Medicine Technology:Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing 2Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing 3Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 2SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5Pharmasset Appoints Michael Rogers as Chief Development Officer 1664 1Pharmasset Appoints Michael Rogers as Chief Development Officer 1664 2Pharmasset Appoints Michael Rogers as Chief Development Officer 1664 3Renovis to Present at CIBC World Markets Healthcare Conference 1661 1Symmetry Medical to Provide Third Quarter 2007 General Business Update on November 7 2007 1658 1Symmetry Medical to Provide Third Quarter 2007 General Business Update on November 7 2007 1658 2Pharmacopeia Announces Third Quarter 2007 Financial Results 727 1Pharmacopeia Announces Third Quarter 2007 Financial Results 727 2Pharmacopeia Announces Third Quarter 2007 Financial Results 727 3Pharmacopeia Announces Third Quarter 2007 Financial Results 727 4Pharmacopeia Announces Third Quarter 2007 Financial Results 727 5Pharmacopeia Announces Third Quarter 2007 Financial Results 727 6Pharmacopeia Announces Third Quarter 2007 Financial Results 727 7Pharmacopeia Announces Third Quarter 2007 Financial Results 727 8Pharmacopeia Announces Third Quarter 2007 Financial Results 727 9Pharmacopeia Announces Third Quarter 2007 Financial Results 727 10Pharmacopeia Announces Third Quarter 2007 Financial Results 727 11...nical Studies Suggest FTY720 Mechanisms in Multipl...in , · Preclinical studies suggest FTY720 s...tion and enhance repair of the,CNS affected by mul...om the six-month multiple,sclerosis Phase II clini...th clinical depression was significantly lower in ...
... Conference Call Scheduled for Friday, May 4, at 9...CO, May 03, 2007 /PRNewswire-FirstCall/ --,Medivat...ild and,moderate subgroups of Alzheimer,s disease ...cy study of Dimebon showed that both,subgroups wer...on,all five efficacy endpoints studied. , The mean...
Other Medicine Technology:Data to be presented at AAN Meeting -Study results of drug,candidate for MS 2Data to be presented at AAN Meeting -Study results of drug,candidate for MS 3Data to be presented at AAN Meeting -Study results of drug,candidate for MS 4Data to be presented at AAN Meeting -Study results of drug,candidate for MS 5Data to be presented at AAN Meeting -Study results of drug,candidate for MS 6Data to be presented at AAN Meeting -Study results of drug,candidate for MS 7Data to be presented at AAN Meeting -Study results of drug,candidate for MS 8Data to be presented at AAN Meeting -Study results of drug,candidate for MS 9Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 2Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 3Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 4Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 5